VERASTEM INC

VSTM is the Nasdaq ticker for Verastem, Inc., a biopharmaceutical company focused on developing and commercializing therapies for cancer. The stock represents ownership in a clinical-stage and commercial-stage oncology business. Its performance is closely linked to drug development milestones, regulatory decisions, and commercial uptake of its products.

VSTM operates in the competitive oncology biotech space, so its prospects depend on clinical trial data, FDA approvals, and product commercialization. The company has a history of losses and may rely on external financing. Understanding its pipeline, cash runway, and partnership agreements is important for evaluating the risk-return profile.

Recent price action for VSTM is displayed on this page, including the latest quote and percentage change. Biotech stocks like VSTM can move sharply on news such as trial results or regulatory updates. For the most current performance, refer to the live data and charts provided above.

Determining whether VSTM is overvalued or undervalued requires comparing its market value to fundamentals such as revenue, earnings, and pipeline potential. Since the company may not have consistent profits, traditional metrics like P/E may not apply. The latest valuation data on this page can help inform your assessment.

VSTM can be highly volatile due to its biotech focus, where clinical trial outcomes and regulatory news often cause significant price swings. Trading volume may also spike around announcements. Historical price ranges and beta can provide context, and the latest volatility indicators are available on this page.

Key risks include clinical trial failures, regulatory delays, competition from larger pharmaceutical firms, and the need for additional capital. VSTM may also face manufacturing or commercialization challenges. Because it operates in a high-risk sector, its stock can be sensitive to negative news and broader market sentiment.